Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells
暂无分享,去创建一个
R. Swanstrom | N. Archin | K. Robertson | M. Gisslén | J. Eron | P. Menezes | S Spudich | A. Kashuba | S. Joseph | C. Lippincott | P. Kincer | M. Bowman | W. Price | C. Evans | J. Vinikoor
[1] R. Swanstrom,et al. The evolution of HIV‐1 entry phenotypes as a guide to changing target cells , 2018, Journal of leukocyte biology.
[2] G. di Perri,et al. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia , 2018, Journal of NeuroVirology.
[3] J. Mellors,et al. No evidence of HIV replication in children on antiretroviral therapy. , 2017, The Journal of clinical investigation.
[4] J. Lifson,et al. Defining total-body AIDS-virus burden with implications for curative strategies , 2017, Nature Medicine.
[5] Ellen R. Forsyth,et al. Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir , 2017, mBio.
[6] G. Fogel,et al. HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads , 2016, Journal of Virology.
[7] C. Leen,et al. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia , 2016, Journal of NeuroVirology.
[8] Nancie M Archin,et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.
[9] William D. Graham,et al. Phenotypic Correlates of HIV-1 Macrophage Tropism , 2015, Journal of Virology.
[10] P. Mieczkowski,et al. Primer ID Validates Template Sampling Depth and Greatly Reduces the Error Rate of Next-Generation Sequencing of HIV-1 Genomic RNA Populations , 2015, Journal of Virology.
[11] R. Price,et al. Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy , 2015, Current HIV/AIDS Reports.
[12] R. Swanstrom,et al. Affinofile Assay for Identifying Macrophage-Tropic HIV-1. , 2014, Bio-protocol.
[13] J. Mellors,et al. Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.
[14] J. Hoxie,et al. Quantification of Entry Phenotypes of Macrophage-Tropic HIV-1 across a Wide Range of CD4 Densities , 2013, Journal of Virology.
[15] E. L. Potter,et al. Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design , 2013, Journal of Virology.
[16] M. Peluso,et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load , 2012, AIDS.
[17] P. Kubes,et al. Immune surveillance in the central nervous system , 2012, Nature Neuroscience.
[18] A. Phillips,et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] R. Price,et al. Antiretroviral drug treatment of CNS HIV-1 infection. , 2012, The Journal of antimicrobial chemotherapy.
[20] R. Swanstrom,et al. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types , 2011, PLoS pathogens.
[21] J. Clements,et al. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system , 2011, Current opinion in HIV and AIDS.
[22] D. Fuchs,et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. , 2010, The Journal of infectious diseases.
[23] S J Gange,et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.
[24] D. Burton,et al. Determinants Flanking the CD4 Binding Loop Modulate Macrophage Tropism of Human Immunodeficiency Virus Type 1 R5 Envelopes , 2009, Journal of Virology.
[25] Joseph A Kovacs,et al. ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.
[26] Steven Wolinsky,et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia , 2006, Proceedings of the National Academy of Sciences.
[27] P. Simmonds,et al. Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis , 2006, Journal of Virology.
[28] W. Cao,et al. HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. , 2006, Virology.
[29] R. Tidwell,et al. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[30] Tara L. Kieffer,et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.
[31] John P. Moore,et al. Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate , 2002, Journal of Virology.
[32] W. Heneine,et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Siliciano,et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.